Phase II study of sunitinib in men with advanced prostate cancer
AUTOR(ES)
Dror Michaelson, M.
FONTE
Oxford University Press
RESUMO
Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2674960Documentos Relacionados
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
- Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
- Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer